Wang X, Du X, Yang H, et al. - Given that a novel recommendation against the routine use of magnesium has been incorporated in the Chinese guidelines for the care of acute myocardial infarction (AMI) in 2001, researchers analyzed temporal trends as well as institutional variation in the use of intravenous magnesium sulfate among people hospitalised with AMI (nationally representative samples) in China between 2001 and 2015 in this observational analysis (China PEACE—Retrospective Study) of AMI care. They reported a significant initial reduction in intravenous magnesium sulfate use over time, from 32.1% in 2001 to 17.1% in 2015. Relative to the Central region, the Eastern and Western regions demonstrated a greater reduction, with little variation between rural and urban regions. Over time, no shift was evident in the proportion of hospitals using intravenous magnesium sulfate. Intravenous magnesium sulfate use was identified to be related to cardiac arrest at admission as well as receipt of reperfusion therapy, but no hospital-specific features. The use of intravenous magnesium sulfate was reported in approximately one in six patients with AMI in China, despite recommendations against its use. The requirement for more efficient mechanisms to stop employing ineffective therapies to enhance patients’ results and decrease medical waste was emphasized.